Is CTXR or TLPH more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -59.57% -34.47% Talphera N/A -87.28% -51.36%

Is ELOX or CTXR more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Citius Pharmaceuticals N/A -59.57% -34.47%

Does the media favor ELOX or CTXR?

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 1 mentions for Citius Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CTXR or INCR?

Citius Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 733.33%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Citius Pharmaceuticals is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CTXR or INCR more profitable?

InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -59.57% -34.47% InterCure N/A N/A N/A

Do analysts recommend RYM or CTXR?

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 733.33%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media prefer SCYX or CTXR?

In the previous week, SCYNEXIS and SCYNEXIS both had 1 articles in the media. SCYNEXIS's average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Citius Pharmaceuticals (CTXR) Competitors

$0.60 +0.01 (+2.06%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.60 -0.01 (-0.83%)

As of 09/18/2026 07:30 PM Eastern

Compare

CTXR vs. TLPH, ELOX, INCR, RYM, and SCYX

Should you buy Citius Pharmaceuticals stock or one of its competitors? Citius Pharmaceuticals's main competitors and comparable companies include Talphera (TLPH), Eloxx Pharmaceuticals (ELOX), InterCure (INCR), RYTHM (RYM), and SCYNEXIS (SCYX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Citius Pharmaceuticals compare to Talphera?

Citius Pharmaceuticals (NASDAQ:CTXR) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Talphera. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for Talphera. Citius Pharmaceuticals' average media sentiment score of 0.00 equaled Talphera'saverage media sentiment score.

Company	Overall Sentiment
Citius Pharmaceuticals	Neutral
Talphera	Neutral

Citius Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Talphera has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Citius Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 733.33%. Talphera has a consensus target price of $3.00, suggesting a potential upside of 158.62%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Citius Pharmaceuticals is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Talphera has higher revenue and earnings than Citius Pharmaceuticals. Talphera is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A
Talphera	$30K	2,007.19	-$14.29M	-$0.27	N/A

Citius Pharmaceuticals' return on equity of -59.57% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
Talphera	N/A	-87.28%	-51.36%

Summary

Citius Pharmaceuticals beats Talphera on 9 of the 13 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Eloxx Pharmaceuticals has higher revenue and earnings than Citius Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	11.08	-$5.99M	-$1.54	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its stock price is 186,326% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Eloxx Pharmaceuticals currently has a consensus price target of $38.33, indicating a potential upside of 119.68%. Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 733.33%. Given Citius Pharmaceuticals' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eloxx Pharmaceuticals' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 1 mentions for Citius Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eloxx Pharmaceuticals beats Citius Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to InterCure?

Citius Pharmaceuticals (NASDAQ:CTXR) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Citius Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 733.33%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Citius Pharmaceuticals is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for InterCure. Citius Pharmaceuticals' average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
Citius Pharmaceuticals	Neutral
InterCure	Neutral

InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
InterCure	N/A	N/A	N/A

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of InterCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Citius Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, InterCure has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

InterCure has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A
InterCure	$78.47M	0.74	-$10.37M	$0.15	35.30

Summary

InterCure beats Citius Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to RYTHM?

RYTHM (NASDAQ:RYM) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than RYTHM. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for RYTHM. RYTHM's average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
RYTHM	Neutral
Citius Pharmaceuticals	Neutral

6.0% of RYTHM shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

RYTHM has a beta of 9.44, indicating that its stock price is 844% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Citius Pharmaceuticals has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

RYTHM has higher revenue and earnings than Citius Pharmaceuticals. RYTHM is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.83	-$33.26M	-$10.53	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 733.33%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Citius Pharmaceuticals beats RYTHM on 9 of the 14 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Citius Pharmaceuticals has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-44.15%	-32.61%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

SCYNEXIS has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

SCYNEXIS presently has a consensus target price of $33.00, indicating a potential upside of 639.91%. Citius Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 733.33%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

SCYNEXIS has higher revenue and earnings than Citius Pharmaceuticals. SCYNEXIS is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.15	-$8.61M	-$2.09	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, SCYNEXIS and SCYNEXIS both had 1 articles in the media. SCYNEXIS's average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Citius Pharmaceuticals beats SCYNEXIS on 7 of the 13 factors compared between the two stocks.

Get Citius Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTXR vs. The Competition

Export

Metric	Citius Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.47M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-0.36	797.25	275.49	25.40
Price / Sales	N/A	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	0.14	10.53	10.46	6.33
Net Income	-$37.43M	$2.82B	$3.49B	$358.33M
7 Day Performance	3.27%	1.69%	0.59%	1.12%
1 Month Performance	0.03%	0.24%	-1.74%	-2.39%
1 Year Performance	-49.58%	3.95%	18.13%	5.35%

Citius Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTXR Citius Pharmaceuticals	1.8186 of 5 stars	$0.60 +2.1%	$5.00 +733.3%	-49.6%	$16.47M	N/A	N/A	20	Gap Up
TLPH Talphera	1.9452 of 5 stars	$1.20 flat	$3.00 +150.0%	+36.5%	$62.29M	$30K	N/A	19
ELOX Eloxx Pharmaceuticals	2.4476 of 5 stars	$15.00 flat	$41.50 +176.7%	N/A	$60.55M	$6.36M	N/A	N/A	News Coverage Analyst Forecast Gap Up
INCR InterCure	1.1813 of 5 stars	$5.42 flat	N/A	-27.5%	$59.28M	$78.47M	36.13	350
RYM RYTHM	0.4229 of 5 stars	$25.71 -2.0%	N/A	N/A	$57.20M	$17.28M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTXR) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. TLPH, ELOX, INCR, RYM, and SCYX

How does Citius Pharmaceuticals compare to Talphera?

Summary

How does Citius Pharmaceuticals compare to Eloxx Pharmaceuticals?

Summary

How does Citius Pharmaceuticals compare to InterCure?

Summary

How does Citius Pharmaceuticals compare to RYTHM?

Summary

How does Citius Pharmaceuticals compare to SCYNEXIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. TLPH, ELOX, INCR, RYM, and SCYX

How does Citius Pharmaceuticals compare to Talphera?

Does the media refer more to CTXR or TLPH?

Which has more volatility and risk, CTXR or TLPH?

Do insiders and institutionals hold more shares of CTXR or TLPH?

Do analysts rate CTXR or TLPH?

Which has preferable earnings & valuation, CTXR or TLPH?

Is CTXR or TLPH more profitable?

Summary

How does Citius Pharmaceuticals compare to Eloxx Pharmaceuticals?

Which has preferable valuation & earnings, ELOX or CTXR?

Which has more volatility & risk, ELOX or CTXR?

Do analysts prefer ELOX or CTXR?

Do insiders and institutionals hold more shares of ELOX or CTXR?

Is ELOX or CTXR more profitable?

Does the media favor ELOX or CTXR?

Summary

How does Citius Pharmaceuticals compare to InterCure?

Do analysts recommend CTXR or INCR?

Does the media refer more to CTXR or INCR?

Is CTXR or INCR more profitable?

Do institutionals and insiders believe in CTXR or INCR?

Which has more volatility & risk, CTXR or INCR?

Which has higher earnings and valuation, CTXR or INCR?

Summary

How does Citius Pharmaceuticals compare to RYTHM?

Does the media prefer RYM or CTXR?

Do institutionals & insiders hold more shares of RYM or CTXR?

Which has more volatility and risk, RYM or CTXR?

Is RYM or CTXR more profitable?

Which has higher valuation and earnings, RYM or CTXR?

Do analysts recommend RYM or CTXR?

Summary

How does Citius Pharmaceuticals compare to SCYNEXIS?

Is SCYX or CTXR more profitable?

Which has more volatility and risk, SCYX or CTXR?

Do analysts rate SCYX or CTXR?

Which has preferable earnings & valuation, SCYX or CTXR?

Do insiders and institutionals believe in SCYX or CTXR?

Does the media prefer SCYX or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools